Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Chairman operating in the Health Diagnostics space. If you think a Chairman is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Peter Allen
Chairman of Oxford Nanopore Technologies
Peter Allen joined the board of Oxford Nanopore in 2011, bringing broad, senior experience in the life sciences industries. He currently serves as Non-Executive Chairman on the Boards of ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen Neuroscience plc. Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech’s flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.
Follow Peter Allen:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Gunter Dombrowe
Non-Executive Chairman of Adaptix Ltd
Follow Gunter Dombrowe:
About : Adaptix is transforming planar X-ray – the diagnostic imaging modality most widely used in healthcare worldwide.
Paul Cowan
Founder , Chairman & Chief Executive Officer of Quotient Biodiagnostics
Paul Cowan is our Chief Executive Officer and Chairman of our Board of Directors. Mr. Cowan founded us through the acquisition of Alba Bioscience in 2007. He has a broad range of healthcare industry experience gained through over 15 years of employment within industry and investment banking. Previously, Mr. Cowan served as the Chief Financial Officer of Inveresk Research Group, a global contract research organization that was acquired by Charles River Laboratories in 2004. Prior to joining Inveresk in 2001, Mr. Cowan was a senior executive within the Investment Banking department of Bear Stearns & Co., where he led the European biotechnology practice. Prior to Bear Stearns, Mr. Cowan was a senior executive within the Investment Banking department of Morgan Grenfell (acquired by Deutsche Bank in 1990). Mr. Cowan received a Bachelor of Business in accounting from Queensland University of Technology.
Follow Paul Cowan:
About Quotient Biodiagnostics: Quotient Biodiagnostics develops and manufactures products for use in transfusion diagnostics.
Chris Hand
Chairman of Abingdon Health
Follow Chris Hand:
About Molecular Vision: Abingdon Health is an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.
Richard Farleigh
Chairman of Oxonica
Richard studied economics and mathematics, before working at the Australian Central Bank and then becoming an investment banker and hedge fund manager. In 1994 Richard branched out on his own as a private backer of emerging businesses. He has since backed over 50 young, mostly UK-based technology companies, including Amino Technologies, ARC International, Celoxica, ClearSpeed Technology, Cmed Group, Radiation Watch, Wolfson Microelectronics, Green Chemicals – and Oxonica. Richard is author of the investment book, Taming the Lion, and has appeared in the BBC series Dragon’s Den. He joined Oxonica in July 2007.
Follow Richard Farleigh:
About Oxonica: Oxonica develops and commercializes advanced nanomaterials for UV protection, security, and biodiagnostics applications.
Jonathan Glenn
Chairman of Tissue Regenix
Follow Jonathan Glenn:
About Tissue Regenix: Tissue Regenix commercializes innovative technologies in regenerative medicine.
Mark Hurley
Chairman of Biofortuna
Follow Mark Hurley:
About : Biofortuna develops a range of molecular diagnostic products using proprietary freeze-dried technology.
Bill Potter
Executive Chairman of Futura Medical
William Potter became Chairman in June 2001. He is an adviser to the Nominations Committee and to the Remuneration Committee. He provides advice and expertise on product development matters bringing to bear his considerable experience. He has over 30 years of experience in research and development including bringing new products to market involving a wide range of medical devices. He has extensive knowledge of worldwide regulatory procedures, intellectual property issues and licensing. Dr Potter previously worked at London International Group plc, including seven years as Group Scientific Affairs Director, and at Smith & Nephew plc.
Follow Bill Potter:
About Futura Medical: Futura’s innovation strategy applies advanced science to develop products with compelling commercial potential using our advanced
Sheraz Daya
Founder, Chairman & Medical Director of Centre for Sight
Follow Sheraz Daya:
About Centre for Sight: Centre for Sight provides eye care services, from basic diagnostic and therapeutic services to complex operative procedures.
